NASDAQ:PAVM - PAVmed Stock Price, Forecast & News

PAVmed trades on the NASDAQ under the ticker symbol "PAVM."

PAVmed Inc (NASDAQ:PAVM) posted its quarterly earnings results on Thursday, November, 15th. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.04. View PAVmed's Earnings History.

PAVmed is scheduled to release their next quarterly earnings announcement on Thursday, April 2nd 2020. View Earnings Estimates for PAVmed.

1 Wall Street analysts have issued 1 year price targets for PAVmed's stock. Their forecasts range from $5.00 to $5.00. On average, they anticipate PAVmed's stock price to reach $5.00 in the next year. This suggests a possible upside of 115.5% from the stock's current price. View Analyst Price Targets for PAVmed.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PAVmed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PAVmed.

Media stories about PAVM stock have been trending very negative on Thursday, InfoTrie reports. The research group identifies negative and positive press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. PAVmed earned a news sentiment score of -3.7 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for PAVmed.

PAVmed saw a drop in short interest in January. As of January 31st, there was short interest totalling 832,500 shares, a drop of 10.3% from the January 15th total of 928,100 shares. Based on an average trading volume of 576,000 shares, the short-interest ratio is currently 1.4 days. Approximately 3.1% of the shares of the company are sold short. View PAVmed's Current Options Chain.

Some companies that are related to PAVmed include Alphatec (ATEC), OraSure Technologies (OSUR), Inovio Pharmaceuticals (INO), Utah Medical Products (UTMD), Restoration Robotics (HAIR), Iradimed (IRMD), SeaSpine (SPNE), Repro-Med Systems (REPR), Accuray (ARAY), Repro Med Systems (KRMD), Westaim (WEDXF), Apyx Medical (APYX), Venus Concept (VERO), iCAD (ICAD) and GenMark Diagnostics (GNMK).

Based on aggregate information from My MarketBeat watchlists, some companies that other PAVmed investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Tonix Pharmaceuticals (TNXP), Co-Diagnostics (CODX), Onconova Therapeutics (ONTX), AVEO Pharmaceuticals (AVEO), Achieve Life Sciences (ACHV), Genprex (GNPX), Opko Health (OPK) and Nokia Oyj (NOK).

PAVmed's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Levin Capital Strategies L.P. (0.16%) and Virtu Financial LLC (0.05%). Company insiders that own PAVmed stock include Dennis M Mcgrath, Ira Scott Greenspan and Lishan Aklog. View Institutional Ownership Trends for PAVmed.

PAVM stock was purchased by a variety of institutional investors in the last quarter, including Levin Capital Strategies L.P. and Virtu Financial LLC. Company insiders that have bought PAVmed stock in the last two years include Dennis M Mcgrath and Lishan Aklog. View Insider Buying and Selling for PAVmed.

Shares of PAVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PAVM stock can currently be purchased for approximately $2.32.

PAVmed has a market capitalization of $88.42 million. PAVmed employs 9 workers across the globe.View Additional Information About PAVmed.

The official website for PAVmed is http://www.pavmed.com/.

PAVmed's mailing address is ONE GRAND CENTRAL PLACE SUITE 4600, NEW YORK NY, 10165. The company can be reached via phone at 212-949-4319 or via email at [email protected]